Hubbry Logo
Trans-actingTrans-actingMain
Open search
Trans-acting
Community hub
Trans-acting
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Trans-acting
Trans-acting
Trans-acting
View on Wikipedia
from Wikipedia

In the field of molecular biology, trans-acting (trans-regulatory, trans-regulation), in general, means "acting from a different molecule" (i.e., intermolecular). It may be considered the opposite of cis-acting (cis-regulatory, cis-regulation), which, in general, means "acting from the same molecule" (i.e., intramolecular).

In the context of transcription regulation, a trans-acting factor is usually a regulatory protein that binds to DNA.[1] The binding of a trans-acting factor to a cis-regulatory element in DNA can cause changes in transcriptional expression levels. microRNAs or other diffusible molecules are also examples of trans-acting factors that can regulate target sequences.[2] The trans-acting gene may be on a different chromosome to the target gene, but the activity is via the intermediary protein or RNA that it encodes. Cis-acting elements, on the other hand, do not code for protein or RNA. Both the trans-acting gene and the protein/RNA that it encodes are said to "act in trans" on the target gene.

Transcription factors are categorized as trans-acting factors.

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Trans-acting

View on Grokipedia
from Grokipedia
In molecular biology, trans-acting factors are diffusible regulatory molecules, typically proteins such as transcription factors, that influence gene expression by binding to specific DNA sequences located on separate molecules within the cell. These factors, encoded by genes elsewhere in the genome, can activate or repress transcription of target genes regardless of their physical proximity to those genes, enabling coordinated regulation across the genome. Unlike cis-acting elements, which are non-coding DNA sequences (e.g., promoters or enhancers) that only affect genes on the same DNA molecule, trans-acting factors operate in trans by diffusing through the cell to interact with multiple loci. Trans-acting factors play a central role in eukaryotic gene regulation, where they often function as dimers—either homodimers or heterodimers—that recognize short DNA motifs, such as the cAMP response element (TGACGTCA), to modulate RNA polymerase activity and initiate or inhibit transcription. Their expression levels and activity vary by cell type, developmental stage, and environmental signals, allowing for tissue-specific or inducible gene control; for instance, activators enhance transcription when bound upstream of promoters, while repressors inhibit it, sometimes through interactions with co-regulatory proteins. In genetic studies, mutations in trans-acting factor genes can lead to widespread effects on gene expression networks, contributing to phenotypes in model organisms like yeast and humans. Beyond transcription, trans-acting elements may include non-protein molecules like small RNAs that post-transcriptionally regulate , though proteins remain the predominant class in classical definitions. The concept of trans-acting regulation has been foundational in understanding , evolutionary adaptations, and diseases involving dysregulated gene networks, such as cancer or developmental disorders.

Fundamentals

Definition

Trans-acting elements are diffusible molecules, typically proteins or RNAs, that regulate gene expression by interacting with target genes located on separate DNA molecules or at distant chromosomal loci, enabling them to influence transcription or translation across the genome. These factors function through specific recognition of binding sites on DNA or RNA, rather than being physically linked to the regulated gene itself. The concept of trans-acting elements originated in the 1961 operon model proposed by François Jacob and , who conceptualized bacterial repressors as diffusible products of regulator genes that could act on operator sites to control the expression of structural s in the . This model established the foundational idea of regulatory proteins diffusing within the cell to modulate gene activity coordinately, laying the groundwork for understanding gene regulation in both prokaryotes and eukaryotes. Key characteristics of trans-acting elements include their diffusibility, which allows them to act in trans—meaning across different chromosomes within the cell—and their specificity, achieved via structured domains such as DNA- or RNA-binding motifs that recognize particular sequence elements. Common types encompass transcription factors, which serve as activators or repressors to modulate activity, as well as small RNAs like microRNAs that post-transcriptionally regulate target mRNAs. In contrast to cis-acting elements, which are immobile DNA sequences adjacent to genes, trans-acting factors provide flexible, global control over gene networks.

Comparison to Cis-acting Elements

Cis-acting elements are non-coding DNA sequences, such as promoters, enhancers, and silencers, that regulate gene expression by acting exclusively on the same DNA molecule or chromosome on which they are located, without the ability to diffuse to other molecules. In contrast to trans-acting factors, which are diffusible molecules like proteins that can influence genes across different chromosomes, cis-acting elements remain immobile and provide localized control over nearby genes. The distinctions between trans-acting and cis-acting elements can be summarized in the following table:
AspectTrans-acting ElementsCis-acting Elements
MobilityDiffusible (e.g., proteins that move freely within the cell)Immobile (fixed DNA sequences bound to the chromosome)
Genetic Test (Complementation)Mutations can be complemented by a wild-type copy on a separate chromosome, as the factor diffusesMutations affect only the linked gene and cannot be rescued by a wild-type copy elsewhere
ExamplesTranscription factors (e.g., PAX6 binding to distant enhancers)Promoters (e.g., TATA box), enhancers (e.g., E4 enhancer of Fezf2)
Evolutionary ImplicationsEnable coordinated regulation of multiple genes across the genome, evolving through changes in protein specificityFacilitate local, gene-specific adaptations, evolving via sequence mutations in conserved regions
A key method to distinguish these elements is the genetic complementation test, where a mutation in a trans-acting factor can be rescued by introducing a wild-type copy on a different chromosome, allowing the diffusible product to restore function genome-wide; in contrast, cis-acting mutations remain unrescued because the defective DNA sequence cannot be compensated by a separate molecule. From an evolutionary standpoint, trans-acting elements promote broad, coordinated changes in gene regulation across the , such as through alterations in binding affinities that affect multiple targets, while cis-acting elements allow precise, local control that can drive species-specific traits without widespread disruption. Cis effects often predominate in interspecies differences, particularly in promoters, whereas trans effects are more prominent in enhancer evolution due to their role in network redundancy.

Mechanisms

In Transcription

Trans-acting transcription factors (TFs) play a central role in regulating transcription by binding to specific cis-acting elements, such as promoters and enhancers, to facilitate the recruitment of (Pol II) in eukaryotes. These soluble proteins recognize DNA sequences through their DNA-binding domains and interact with the basal transcription machinery to initiate pre-initiation complex (PIC) assembly at gene promoters. In this process, TFs bridge distant enhancers and promoters, often via looping mechanisms, to enhance Pol II loading and transcription start site selection. The mechanisms of transcriptional regulation by TFs involve distinct activation and repression pathways. Activation typically occurs through acidic or glutamine-rich activation domains in TFs that interact with co-activators like the Mediator complex, which in turn bridges TFs to Pol II and promotes PIC formation and promoter clearance. For repression, TFs recruit histone deacetylases (HDACs) to compact chromatin and inhibit Pol II activity by reducing histone acetylation and blocking access to DNA. A typical TF-DNA-protein complex consists of the TF's DNA-binding domain clamped onto a specific promoter or enhancer sequence, with its activation domain extending to contact the globular head and tail modules of the Mediator complex, which docks onto Pol II's clamp domain, forming a stable scaffold for transcription initiation; this architecture is visualized in structural studies as a multi-subunit assembly where TF-Mediator interactions stabilize the PIC. TF specificity arises from their modular architecture, comprising DNA-binding domains (e.g., motifs that insert alpha-helices into the DNA major groove for sequence readout), activation domains for co-activator recruitment, and repression domains for modifiers. , common in eukaryotic TFs, enable high-affinity binding to 3–4 motifs, allowing recognition of diverse cis-elements. Combinatorial control enhances specificity and regulatory precision, where multiple TFs bind cooperatively to adjacent sites on enhancers or promoters, synergizing to amplify transcription rates beyond additive effects. The binding affinity of TFs to DNA can be quantitatively modeled using the Hill equation, which accounts for cooperative interactions: θ=[TF]nKd+[TF]n\theta = \frac{[\text{TF}]^n}{K_d + [\text{TF}]^n} Here, θ\theta represents fractional occupancy, [TF][\text{TF}] is the TF concentration, KdK_d is the dissociation constant, and nn (the Hill coefficient) quantifies cooperativity, with n>1n > 1 indicating synergistic binding that sharpens response thresholds in gene expression. This model is essential for understanding how low TF concentrations can drive sharp transcriptional switches. In , trans-acting regulation includes sigma factors—subunits of that direct promoter recognition—as well as separate DNA-binding TFs for specific control, allowing rapid adaptation via sigma exchange or TF modulation, whereas eukaryotic systems employ hundreds of complex, multi-domain TFs for fine-tuned, combinatorial control amid barriers.

In Translation

Trans-acting factors play a crucial role in regulating the translation of mRNA into proteins by interacting with ribosomes, mRNA, and other components in the cytoplasm. These factors include eukaryotic initiation factors (eIFs), such as eIF4E, eIF4G, and eIF4A, which facilitate the assembly of the ribosomal initiation complex; elongation factors (eEFs), like eEF1A and eEF2, which promote aminoacyl-tRNA delivery and ribosomal translocation; and release factors (eRF1 and eRF3), which terminate translation upon recognition of stop codons. Key mechanisms involve cap-dependent , where the subunit of the eIF4F complex binds the 5' m7G cap structure of mRNA to recruit the 43S preinitiation complex, while the poly(A)-binding protein (PABP) interacts with eIF4G to circularize the mRNA, enhancing efficiency by stabilizing the initiation complex and promoting reinitiation. Regulation often occurs through ; for instance, the pathway phosphorylates 4E-BP1, relieving its inhibition of and thereby activating cap-dependent in response to nutrient availability. Elongation proceeds with eEF1A delivering charged tRNAs to the A site and catalyzing translocation, while release factors trigger to dissociate the post-termination. Repression of translation by trans-acting factors can occur via miRNA-bound proteins, which form the (RISC) and inhibit by competing with for access or blocking ribosomal scanning along the (UTR). In the ribosome scanning model, the 40S small ribosomal subunit, loaded with the eIF2-GTP-Met-tRNAi ternary complex, binds near the 5' via eIF4F and scans downstream to identify the (AUG), a process facilitated by eIF1 and eIF1A to ensure accurate ; disruptions, such as by , halt this scanning and prevent 60S joining. A basic kinetic model describes the rate vv as proportional to mRNA and charged tRNA concentrations, v=k⋅[mRNA]⋅[tRNA]v = k \cdot [mRNA] \cdot [tRNA], where the rate constant kk is modulated by trans-acting factor levels, such as eIFs influencing frequency or eEFs affecting elongation speed. Unlike transcription, which is nuclear and DNA-templated, translation is post-transcriptional and confined to the , allowing rapid responses to local conditions; for example, under cellular stress like deprivation or ER stress, phosphorylation of eIF2α by kinases such as PERK inhibits ternary complex formation, globally halting while selectively allowing of stress-response mRNAs.

Examples

Transcription Factors

Transcription factors are proteins that bind to specific DNA sequences to regulate , functioning as trans-acting elements by diffusing through the cell to interact with distant genomic sites. A classic prokaryotic example is the (LacI) in , which binds to the operator sequence of the to prevent from initiating transcription of genes involved in metabolism. This repression is relieved when , a derivative, binds to LacI, inducing a conformational change that releases it from the DNA. Genetic experiments using partial diploids, where cells carried both wild-type and mutant lac operons on separate , demonstrated LacI's trans-acting nature: a functional LacI from one chromosome repressed the operon on the other, confirming its diffusible protein form. In eukaryotes, serves as a tumor suppressor that activates genes for in response to cellular stress, such as DNA damage, by binding to p53 response elements in promoter regions. For instance, p53 upregulates genes like GADD45 and PCNA to facilitate and arrest, preventing propagation of mutations. Similarly, is a dimeric central to inflammatory responses; upon stimulation by cytokines or pathogens, its p65/p50 subunits translocate from the to the nucleus, where they bind κB sites to induce proinflammatory genes such as TNF-α and IL-6. This nuclear translocation is regulated by IκB degradation via the canonical NF-κB pathway, enabling rapid immune activation. Many transcription factors, particularly homeodomain proteins like those in the Hox family, feature a (HTH) motif in their , consisting of two alpha helices connected by a short turn that recognizes specific DNA sequences for developmental patterning. Hox proteins, expressed along the anterior-posterior axis in embryos, use this HTH structure within their 60-amino-acid homeodomain to bind TAAT-core motifs, directing segment identity and organ formation; for example, HoxB1 regulates development by activating rhombomere-specific genes. Disruptions in Hox HTH binding can lead to congenital malformations, underscoring their role in precise spatial gene regulation. Experimental techniques like followed by sequencing (ChIP-seq) have provided genome-wide evidence of binding, revealing thousands of sites per factor with high specificity and occupancy patterns that correlate with regulatory activity. For example, ChIP-seq of in human cells identifies enriched peaks at response elements near loci, confirming its trans-regulatory scope across the genome. Mutations in also highlight their functional importance; in , defects in erythroid factors like KLF1 (Krüppel-like factor 1) cause dysregulated production, leading to through impaired β-globin activation, as seen in congenital dyserythropoietic variants. Similarly, mutations disrupt erythroid differentiation, contributing to β-thalassemia-like phenotypes with . The encodes over 1,600 transcription factors, exhibiting diversity in DNA-binding domains that dictate specificity and function. These are classified into families such as basic helix-loop-helix (bHLH) proteins, which dimerize via a to bind sequences (CANNTG) and regulate and , and nuclear receptors like , which bind hormone-response elements upon activation to modulate and immunity. This structural variety enables combinatorial control of across cellular contexts.

Regulatory RNAs and Proteins

MicroRNAs (miRNAs) are small non-coding RNAs approximately 22 nucleotides in length that function as trans-acting regulators of post-transcriptional . They are processed from primary miRNA (pri-miRNA) transcripts, which are transcribed by and form stem-loop structures; these are cleaved by the nuclear microprocessor complex containing and DGCR8 to generate precursor miRNAs (pre-miRNAs), which are then exported to the cytoplasm and further processed by into mature miRNAs. Mature miRNAs are loaded into the (RISC), where proteins facilitate base-pairing with target mRNAs, primarily at the 3' untranslated regions (UTRs), leading to mRNA degradation or translational repression through deadenylation and mechanisms. Small interfering RNAs (siRNAs) mediate (RNAi), a conserved post-transcriptional silencing pathway, and can be exogenous or endogenous in origin. Exogenous siRNAs, often introduced experimentally or derived from viral infections, are double-stranded RNAs that are diced into 21-23 duplexes by and incorporated into RISC, where the guide strand directs precise cleavage of complementary target mRNAs via the slicer activity of Argonaute-2. Endogenous siRNAs arise from bidirectional transcription or transposon-derived precursors and similarly trigger mRNA cleavage or silencing, contributing to defense and developmental regulation. RNA-binding proteins (RBPs) represent another class of trans-acting factors that modulate post-transcriptional RNA processing, stability, and localization. For instance, HuR (ELAV-like protein 1) binds to AU-rich elements in the 3' UTRs of target mRNAs, promoting their stabilization and enhancing expression of genes involved in cell growth and survival, such as those encoding cyclins and proto-oncoproteins. In contrast, FUS (fused in sarcoma) regulates alternative splicing by binding to intronic and exonic sequences, influencing neuronal gene expression; mutations in FUS disrupt nuclear localization and splicing fidelity, contributing to neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), where aggregated FUS impairs RNA metabolism in motor neurons. A notable viral example is the Tat protein, a trans-acting factor that binds to the trans-activation response () RNA element in nascent viral transcripts, recruiting the positive transcription elongation factor b (P-TEFb) to enhance processivity and boost HIV-1 transcription elongation. This mechanism exemplifies how viral proteins can hijack host post-transcriptional machinery for efficient . miRNA targets are commonly predicted based on complementarity to the miRNA seed sequence (nucleotides 2-8 at the 5' end), with conserved matches in 3' UTRs indicating functional sites; experimental validation often employs luciferase reporter assays, where fusion of the putative target UTR to a gene results in reduced reporter activity upon miRNA co-expression, confirming repression.

Biological Significance

Role in Gene Regulation

Trans-acting factors play a pivotal role in network-level regulation by enabling coordinated, global responses to environmental cues, such as stress-induced transcription factors that activate multiple downstream genes simultaneously. For instance, in heat shock responses, factors like heat shock factor (HSF) and GAGA-associated factor (GAF) orchestrate the expression of numerous protective genes by binding to enhancers and promoters across the genome, allowing rapid and widespread transcriptional reprogramming. This diffusible nature of trans-acting elements facilitates the integration of signals from various pathways, promoting adaptive gene expression networks that respond to stressors like temperature changes or oxidative damage. Feedback loops involving trans-acting factors enhance the robustness and precision of regulation through mechanisms like autoregulation and feed-forward motifs. In autoregulation, a can repress its own to maintain steady-state levels, preventing overproduction and ensuring stable circuit dynamics. Feed-forward loops, where one trans-acting factor regulates both a target and an intermediary regulator, filter noise and accelerate response times, as seen in coherent feed-forward architectures that detect fold-changes in input signals rather than absolute levels. These motifs contribute to the reliability of regulatory networks by buffering fluctuations and enabling precise temporal control of . From an evolutionary perspective, trans-acting genes offer advantages in duplication and divergence compared to cis-elements, as their protein products can readily acquire new functions without disrupting existing targets. Duplicated trans-acting loci, such as genes, evolve under less constraint, allowing neofunctionalization that rewires regulatory networks across the more efficiently than localized cis-mutations. This facilitates coordinated evolutionary changes in patterns, contributing to phenotypic diversity in multicellular organisms. Quantitative modeling of trans-acting factor circuits often employs networks for discrete state transitions or ordinary differential equations (ODEs) to capture continuous dynamics, revealing how these elements influence target expression. In ODE frameworks, the concentration of a [TF] evolves as d[TF]dt=production rate−degradation rate\frac{d[\text{TF}]}{dt} = \text{production rate} - \text{degradation rate}, where production depends on upstream activators and degradation ensures , thereby modulating the activation of multiple targets. models complement this by simulating logical gates () in TF interactions, highlighting emergent properties like in feedback-regulated networks. Trans-acting modifiers integrate with epigenetic mechanisms, such as TET enzymes that indirectly influence by oxidizing to , promoting demethylation at distant loci. These enzymes, acting as diffusible factors, coordinate epigenetic landscapes across the , enabling heritable changes in accessibility without direct sequence alteration. This interplay allows trans-acting elements to fine-tune long-term regulatory states in response to developmental signals.

Implications in Development and Disease

Trans-acting elements, such as Hox transcription factors (TFs), play crucial roles in embryonic development by establishing body patterning along the anterior-posterior axis through spatially restricted expression and concentration gradients that mimic effects. In , knockout studies of individual , such as or , result in homeotic transformations where one body segment develops the identity of another, underscoring their essential function in specifying segmental identities. These findings from model organisms highlight how disruptions in trans-acting Hox factors can lead to severe developmental malformations, as observed in vertebrate homologs where similar knockouts alter formation. Dysregulation of trans-acting TFs contributes to various diseases, particularly cancers, where amplification of the drives transcriptional amplification and promotes tumor progression in up to 70% of human malignancies. For instance, amplification enhances global , fueling uncontrolled and metastasis in cancers like and . In autoimmune diseases, hyperactivity of the trans-acting TF sustains chronic inflammation by upregulating pro-inflammatory cytokines, as seen in and systemic lupus erythematosus where aberrant signaling exacerbates immune dysregulation. Therapeutic strategies targeting trans-acting factors have advanced significantly, with CRISPR-based editing enabling precise modulation of TF activity to correct disease-causing mutations. For example, CRISPR activation (CRISPRa) and interference (CRISPRi) systems allow tunable upregulation or repression of TFs in vivo, showing promise in preclinical models for restoring gene regulation in genetic disorders. RNA therapeutics, such as antisense oligonucleotides (ASOs) targeting miRNAs—key trans-acting regulators—have been investigated in clinical trials; antimiRs like miravirsen inhibit miR-122 to treat hepatitis C, demonstrating efficacy in sequestering pathological miRNAs without off-target effects. A prominent case study is , caused by loss-of-function mutations in the MECP2 gene encoding a trans-acting transcriptional repressor that binds methylated DNA to silence . These mutations lead to global transcriptional and translational repression in neurons, resulting in neurodevelopmental deficits like seizures and motor impairments. In the , advances in TF inhibitors for precision medicine have focused on small-molecule disruptors of -MAX interactions, with preclinical studies showing tumor regression in MYC-driven models; some indirect MYC inhibitors have entered early clinical trials (phase I) as of 2024. Emerging research using single-cell RNA sequencing (scRNA-seq) has revealed heterogeneity in tumors, including variable expression across cancer cells that contributes to subclonal diversity and therapy resistance. This intra-tumor variability highlights trans-acting factors as key mediators of evolutionary dynamics in solid tumors.

References

  1. http://www.columbia.edu/cu/biology/courses/c2006/lectures06/lect10.06.html
  2. https://www.ncbi.nlm.nih.gov/books/NBK28086/
  3. https://web.pdx.edu/~newmanl/ChapterOutlines/Chapter11.html
  4. https://www.nature.com/articles/nrg3891
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC3104267/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4382006/
  7. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02110-3
  8. https://www.cell.com/fulltext/S0092-8674%2814%2901097-6
  9. https://www.cell.com/fulltext/S0092-8674%2803%2901078-X
  10. https://www.cell.com/trends/biochemical-sciences/abstract/S0968-0004%2805%2900083-6
  11. https://www.cell.com/cell/pdf/S0092-8674%2818%2931398-9.pdf
  12. https://www.cell.com/fulltext/S0092-8674%2800%2980218-4
  13. https://www.cell.com/cell/fulltext/S0092-8674%2818%2930106-5
  14. https://www.nature.com/articles/cddiscovery201771
  15. https://www.cell.com/developmental-cell/fulltext/S1534-5807%2824%2900603-8
  16. https://www.cell.com/cell/fulltext/S0092-8674%2816%2930741-3
  17. https://www.nature.com/scitable/topicpage/rna-transcription-by-rna-polymerase-prokaryotes-vs-961/
  18. https://www.nature.com/articles/nm938.pdf
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2704942/
  20. https://biosignaling.biomedcentral.com/articles/10.1186/s12964-020-00607-9
  21. https://www.nature.com/articles/s41392-024-01749-9
  22. https://royalsocietypublishing.org/doi/10.1098/rsob.200292
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC8049097/
  24. https://www.tandfonline.com/doi/full/10.1080/15476286.2020.1766179
  25. https://www.pnas.org/doi/10.1073/pnas.0506482102
  26. https://genesdev.cshlp.org/content/16/22/2906.full
  27. https://academic.oup.com/nar/article/41/1/586/1159551
  28. https://www.nature.com/articles/s41467-022-29515-x
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC6028073/
  30. https://www.embopress.org/doi/10.15252/embr.201642195
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC3592455/
  32. https://www.sciencedirect.com/topics/medicine-and-dentistry/lac-repressor
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4852800/
  34. https://www.nature.com/articles/sigtrans201723
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10216783/
  36. https://www.nature.com/articles/6800847
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC2917543/
  38. https://www.sciencedirect.com/science/article/pii/S0002929710005264
  39. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00091/full
  40. https://www.sciencedirect.com/science/article/pii/S0092867418301065
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC463060/
  42. https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/wrna.14
  43. https://www.embopress.org/doi/10.1093/emboj/17.12.3461
  44. https://genesdev.cshlp.org/content/31/15/1509
  45. https://www.mdpi.com/2409-9279/4/1/1
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC6036639/
  47. https://genesdev.cshlp.org/content/30/15/1731.short
  48. https://www.cell.com/current-biology/fulltext/S0960-9822%2809%2900552-1
  49. https://www.pnas.org/doi/10.1073/pnas.2133841100
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC2896310/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3875864/
  52. https://www.nature.com/articles/s41540-024-00380-2
  53. https://www.sciencedirect.com/science/article/pii/S200103701930460X
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4826392/
  55. https://www.nature.com/articles/s41392-023-01537-x
  56. http://www.nature.com/scitable/topicpage/hox-genes-in-development-the-hox-code-41402
  57. https://www.cell.com/current-biology/fulltext/S0960-9822%2815%2901415-3
  58. https://www.cell.com/neuron/fulltext/S0896-6273%2813%2900851-9
  59. https://www.cell.com/fulltext/S0092-8674%2812%2901057-4
  60. https://www.nature.com/articles/s41392-018-0008-7
  61. https://www.nature.com/articles/s41392-020-00312-6
  62. https://www.nature.com/articles/s41392-023-01309-7
  63. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016%2823%2900145-4
  64. https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147%2821%2900077-8
  65. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909%2813%2900401-3
  66. https://www.cell.com/neuron/fulltext/S0896-6273%2824%2900245-9
  67. https://www.nature.com/articles/s41392-021-00500-y
  68. https://www.nature.com/articles/s41591-024-02805-1
Add your contribution
Related Hubs
User Avatar
No comments yet.